Vertex brings a long time pharma deal with Janssen to an end by sell its royalty rights on INCIVO net sales. 

Vertex pharma deal with Janssen started back in 2006, when both collaborated to research and devlope the compound VX-950 / telaprevir as a treatment for Hepatitis c.

Vertex to receive $152 million cash payment from Janssen, subsidiary of Johnson & Johnson,  in 2013.

It will no longer receive royalties on INCIVO sales beginning in 2014.

Janssen will have sole authority to execute INCIVO marketing and promotion activities in these regions.

Ongoing studies will be completed as planned, and the amended agreement accounts for this more streamlined collaboration.

Read the full article on The Boston Globe

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with Johnson & Johnson / Janssen

Report: Hepatitis Partnering

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter